Ascendis Pharma exec exercises, sells 3K shares
Ascendis Pharma A/S (ASND) reports that SVP & PAO Mads Bodenhoff exercised warrants for 3,000 Ordinary Shares on September 8, 2026 at an exercise price of $110.00 per share and on the same date sold 3,000 Ordinary Shares at $270.19 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Ascendis Pharma A/S (ASND) reports that SVP & PAO Mads Bodenhoff exercised warrants for 3,000 Ordinary Shares on September 8, 2026 at an exercise price of $110.00 per share and on the same date sold 3,000 Ordinary Shares at $270.19 per share. Following the exercise, 687 warrants remain outstanding, expiring on October 11, 2032, and no Rule 10b5-1 trading plan is reported.
Insider Trade Summary
Exercise and Sale: 3,000 shares ($481K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Bodenhoff Mads
Role
SVP & PAO
Sold
3,000 shs ($811K)
Approx. gross sale proceeds
$811K
Approx. exercise cost
$330K
Approx. pre-tax spread
$481K
Share of Position Sold
100%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Warrants F1 | 3,000 | $0.00 | $0.00 |
| Exercise | Ordinary Shares | 3,000 | $110.00 | $330K |
| Sale | Ordinary Shares | 3,000 | $270.19 | $811K |
Holdings After Transaction:
Warrants — 687 contracts (Direct);
Ordinary Shares — 0 shares (Direct)
Holdings Before and After:
Warrants, 3,687 to 687 contracts (Direct);
Ordinary Shares, 0 to 0 shares (Direct)
Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (1)
- F1. The warrants vested 25% on October 11, 2023 and thereafter in 36 equal monthly installments.
Key Figures
Warrants exercised: 3,000 warrants
Exercise price: $110.00 per share
Shares sold: 3,000 shares
+5 more
8 metrics
Warrants exercised
3,000 warrants
Exercised into Ordinary Shares on September 8, 2026
Exercise price
$110.00 per share
Exercise price of warrants converted into 3,000 Ordinary Shares
Shares sold
3,000 shares
Ordinary Shares sold on September 8, 2026
Sale price
$270.19 per share
Price for 3,000 Ordinary Shares sold on September 8, 2026
Warrants remaining
687 warrants
Total warrants held directly after the reported exercise
Warrant expiration date
October 11, 2032
Expiration of remaining warrants held by the reporting person
Initial vesting tranche
25%
Warrants vested 25% on October 11, 2023 before monthly installments
Vesting installments
36 monthly installments
Remaining vesting schedule after the initial 25% vesting
Key Terms
warrants, derivative security, Rule 10b5-1
3 terms
warrants financial
"The warrants vested 25% on October 11, 2023 and thereafter in 36 equal"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Rule 10b5-1 regulatory
"no Rule 10b5-1 trading plan is reported for these transactions"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did ASND executive Mads Bodenhoff report on September 8, 2026?
Bodenhoff exercised 3,000 warrants for Ascendis Pharma A/S Ordinary Shares at an exercise price of $110.00 per share and then sold 3,000 Ordinary Shares at $270.19 per share on September 8, 2026.
What was the exercise price of the warrants in the ASND Form 4?
The warrants reported by the Ascendis Pharma A/S SVP & PAO had an exercise price of $110.00 per share, and they were exercised for 3,000 Ordinary Shares on September 8, 2026.
How many warrants does the ASND executive hold after these transactions?
After exercising 3,000 warrants, the Ascendis Pharma SVP & PAO holds 687 warrants directly. These remaining warrants are reported with an expiration date of October 11, 2032.
Were the ASND insider transactions made under a Rule 10b5-1 trading plan?
No. The Form 4 indicates that no Rule 10b5-1 trading plan is reported for these transactions by the Ascendis Pharma A/S SVP & PAO.
What does the footnote say about the vesting of the ASND warrants?
The footnote states that the warrants vested 25% on October 11, 2023 and then vested in 36 equal monthly installments thereafter, describing the vesting schedule for the derivative security that was exercised.
AI-generated analysis. How Rhea-AI works. Not financial advice.
